{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T06:58:00Z","timestamp":1772780280859,"version":"3.50.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2009,7,31]],"date-time":"2009-07-31T00:00:00Z","timestamp":1248998400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2010,4]]},"DOI":"10.1007\/s00417-009-1153-z","type":"journal-article","created":{"date-parts":[[2009,7,30]],"date-time":"2009-07-30T11:32:02Z","timestamp":1248953522000},"page":"457-466","source":"Crossref","is-referenced-by-count":8,"title":["Effect of multiple injections of small divided doses vs single injection of intravitreal bevacizumab on retinal neovascular model in rabbits"],"prefix":"10.1007","volume":"248","author":[{"given":"Saloomeh","family":"Saati","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajat N.","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stan","family":"Louie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerald J.","family":"Chader","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark S.","family":"Humayun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,7,31]]},"reference":[{"key":"1153_CR1","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.exer.2006.03.019","volume":"83","author":"N Rahimi","year":"2006","unstructured":"Rahimi N (2006) Vascular endothelial growth factor receptors: molecular mechanisms of activation and therapeutic potentials. Exp Eye Res 83:1005\u20131016","journal-title":"Exp Eye Res"},{"key":"1153_CR2","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1001\/archopht.122.7.1019","volume":"122","author":"DS Friedman","year":"2004","unstructured":"Friedman DS, O'Colmain BJ, Munoz B, Tomany SC, McCarty C, de Jong PT, Nemesure B, Mitchell P, Kempen J (2004) Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 122:564\u2013572","journal-title":"Arch Ophthalmol"},{"key":"1153_CR3","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1001\/archopht.122.4.552","volume":"122","author":"JH Kempen","year":"2004","unstructured":"Kempen JH, O'Colmain BJ, Leske MC, Haffner SM, Klein R, Moss SE, Taylor HR, Hamman RF (2004) The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol 122:552\u2013563","journal-title":"Arch Ophthalmol"},{"key":"1153_CR4","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1056\/NEJM199412013312203","volume":"331","author":"LP Aiello","year":"1994","unstructured":"Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE et al (1994) Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331:1480\u20131487","journal-title":"N Engl J Med"},{"key":"1153_CR5","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1136\/bjo.80.4.363","volume":"80","author":"JA Wells","year":"1996","unstructured":"Wells JA, Murthy R, Chibber R, Nunn A, Molinatti PA, Kohner EM, Gregor ZJ (1996) Levels of vascular endothelial growth factor are elevated in the vitreous of patients with subretinal neovascularisation. Br J Ophthalmol 80:363\u2013366","journal-title":"Br J Ophthalmol"},{"key":"1153_CR6","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/00006982-200502000-00001","volume":"25","author":"AP Adamis","year":"2005","unstructured":"Adamis AP, Shima DT (2005) The role of vascular endothelial growth factor in ocular health and disease. Retina 25:111\u2013118","journal-title":"Retina"},{"key":"1153_CR7","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/35025215","volume":"407","author":"GD Yancopoulos","year":"2000","unstructured":"Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J (2000) Vascular-specific growth factors and blood vessel formation. Nature 407:242\u2013248","journal-title":"Nature"},{"key":"1153_CR8","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1136\/bjo.2006.098426","volume":"90","author":"RB Bhisitkul","year":"2006","unstructured":"Bhisitkul RB (2006) Vascular endothelial growth factor biology: clinical implications for ocular treatments. Br J Ophthalmol 90:1542\u20131547","journal-title":"Br J Ophthalmol"},{"key":"1153_CR9","doi-asserted-by":"crossref","first-page":"6625","DOI":"10.1074\/jbc.M507783200","volume":"281","author":"G Fuh","year":"2006","unstructured":"Fuh G, Wu P, Liang WC, Ultsch M, Lee CV, Moffat B, Wiesmann C (2006) Structure-function studies of two synthetic anti-vascular endothelial growth factor Fabs and comparison with the Avastin Fab. J Biol Chem 281:6625\u20136631","journal-title":"J Biol Chem"},{"key":"1153_CR10","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1097\/00006982-200603000-00016","volume":"26","author":"RL Avery","year":"2006","unstructured":"Avery RL (2006) Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina 26:352\u2013354","journal-title":"Retina"},{"key":"1153_CR11","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1016\/j.ophtha.2006.11.028","volume":"114","author":"M Cordero Coma","year":"2007","unstructured":"Cordero Coma M, Sobrin L, Onal S, Christen W, Foster CS (2007) Intravitreal bevacizumab for treatment of uveitic macular edema. Ophthalmology 114:1574\u20131579","journal-title":"Ophthalmology"},{"key":"1153_CR12","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1097\/00006982-200603000-00017","volume":"26","author":"FH Davidorf","year":"2006","unstructured":"Davidorf FH, Mouser JG, Derick RJ (2006) Rapid improvement of rubeosis iridis from a single bevacizumab (Avastin) injection. Retina 26:354\u2013356","journal-title":"Retina"},{"key":"1153_CR13","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.ajo.2006.09.014","volume":"143","author":"PT Finger","year":"2007","unstructured":"Finger PT (2007) Anti-VEGF bevacizumab (Avastin) for radiation optic neuropathy. Am J Ophthalmol 143:335\u2013338","journal-title":"Am J Ophthalmol"},{"key":"1153_CR14","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1097\/01.iae.0000247165.38655.bf","volume":"26","author":"C Haritoglou","year":"2006","unstructured":"Haritoglou C, Kook D, Neubauer A, Wolf A, Priglinger S, Strauss R, Gandorfer A, Ulbig M, Kampik A (2006) Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 26:999\u20131005","journal-title":"Retina"},{"key":"1153_CR15","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1007\/s00417-006-0468-2","volume":"245","author":"R Jorge","year":"2007","unstructured":"Jorge R, Costa RA, Calucci D, Scott IU (2007) Intravitreal bevacizumab (Avastin) associated with the regression of subretinal neovascularization in idiopathic juxtafoveolar retinal telangiectasis. Graefes Arch Clin Exp Ophthalmol 245:1045\u20131048","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1153_CR16","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1097\/00006982-200603000-00018","volume":"26","author":"JO Mason 3rd","year":"2006","unstructured":"Mason JO 3rd, Albert MA Jr, Vail R (2006) Intravitreal bevacizumab (Avastin) for refractory pseudophakic cystoid macular edema. Retina 26:356\u2013357","journal-title":"Retina"},{"key":"1153_CR17","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3928\/1542-8877-20050701-15","volume":"36","author":"PJ Rosenfeld","year":"2005","unstructured":"Rosenfeld PJ, Fung AE, Puliafito CA (2005) Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging 36:336\u2013339","journal-title":"Ophthalmic Surg Lasers Imaging"},{"key":"1153_CR18","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3928\/1542-8877-20050701-14","volume":"36","author":"PJ Rosenfeld","year":"2005","unstructured":"Rosenfeld PJ, Moshfeghi AA, Puliafito CA (2005) Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 36:331\u2013335","journal-title":"Ophthalmic Surg Lasers Imaging"},{"key":"1153_CR19","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1111\/j.1600-0420.2006.00779.x","volume":"84","author":"RC Siqueira","year":"2006","unstructured":"Siqueira RC, Costa RA, Scott IU, Cintra LP, Jorge R (2006) Intravitreal bevacizumab (Avastin) injection associated with regression of retinal neovascularization caused by sickle cell retinopathy. Acta Ophthalmol Scand 84:834\u2013835","journal-title":"Acta Ophthalmol Scand"},{"key":"1153_CR20","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/00006982-200603000-00004","volume":"26","author":"RF Spaide","year":"2006","unstructured":"Spaide RF, Fisher YL (2006) Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 26:275\u2013278","journal-title":"Retina"},{"key":"1153_CR21","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/j.1600-0420.2007.01113.x","volume":"86","author":"PV Algvere","year":"2007","unstructured":"Algvere PV, Steen B, Seregard S, Kvanta A (2007) A prospective study on intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration of different durations. Acta Ophthalmol 86:482\u2013489. [pii] AOS1113 doi: 10.1111\/j.1600-0420.2007.01113.x","journal-title":"Acta Ophthalmol"},{"key":"1153_CR22","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s00417-007-0660-z","volume":"246","author":"L Wu","year":"2008","unstructured":"Wu L, Martinez-Castellanos MA, Quiroz-Mercado H, Arevalo JF, Berrocal MH, Farah ME, Maia M, Roca JA, Rodriguez FJ (2008) Twelve-month safety of intravitreal injections of bevacizumab (Avastin(R)): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol 246:81\u201387","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1153_CR23","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1136\/bjo.2007.127142","volume":"92","author":"JF Arevalo","year":"2008","unstructured":"Arevalo JF, Maia M, Flynn HW Jr, Saravia M, Avery RL, Wu L, Eid Farah M, Pieramici DJ, Berrocal MH, Sanchez JG (2008) Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol 92:213\u2013216","journal-title":"Br J Ophthalmol"},{"key":"1153_CR24","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1007\/s00347-007-1634-6","volume":"104","author":"CH Meyer","year":"2007","unstructured":"Meyer CH, Mennel S, Eter N (2007) Incidence of endophthalmitis after intravitreal Avastin injection with and without postoperative topical antibiotic application. Ophthalmologe 104:952\u2013957","journal-title":"Ophthalmologe"},{"key":"1153_CR25","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/j.1600-0420.2007.01067.x","volume":"86","author":"C Shima","year":"2008","unstructured":"Shima C, Sakaguchi H, Gomi F, Kamei M, Ikuno Y, Oshima Y, Sawa M, Tsujikawa M, Kusaka S, Tano Y (2008) Complications in patients after intravitreal injection of bevacizumab. Acta Ophthalmol 86:372\u2013376","journal-title":"Acta Ophthalmol"},{"key":"1153_CR26","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ophtha.2008.10.018","volume":"116","author":"DM Brown","year":"2009","unstructured":"Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T (2009) Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology 116:57\u201365","journal-title":"Ophthalmology"},{"key":"1153_CR27","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419\u20131431","journal-title":"N Engl J Med"},{"key":"1153_CR28","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1007\/s00125-008-0989-9","volume":"51","author":"R Simo","year":"2008","unstructured":"Simo R, Hernandez C (2008) Intravitreous anti-VEGF for diabetic retinopathy: hopes and fears for a new therapeutic strategy. Diabetologia 51:1574\u20131580","journal-title":"Diabetologia"},{"key":"1153_CR29","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/j.ophtha.2006.05.064","volume":"113","author":"RL Avery","year":"2006","unstructured":"Avery RL, Pearlman J, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ, Wendel R, Patel A (2006) Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 113:1695","journal-title":"Ophthalmology"},{"key":"1153_CR30","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.sna.2007.06.034","volume":"143","author":"P-Y Li","year":"2008","unstructured":"Li P-Y, Shih J, Lo R, Saati S, Agrawal R, Humayun MS, Tai Y-C, Meng E (2008) An electrochemical intraocular drug delivery device. Sens Actuators A Phys 143:41\u201348","journal-title":"Sens Actuators A Phys"},{"key":"1153_CR31","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/dmrr.415","volume":"19","author":"RB Caldwell","year":"2003","unstructured":"Caldwell RB, Bartoli M, Behzadian MA, El-Remessy AE, Al-Shabrawey M, Platt DH, Caldwell RW (2003) Vascular endothelial growth factor and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives. Diabetes Metab Res Rev 19:442\u2013455","journal-title":"Diabetes Metab Res Rev"},{"key":"1153_CR32","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.preteyeres.2008.02.002","volume":"27","author":"CJ Pournaras","year":"2008","unstructured":"Pournaras CJ, Rungger-Brandle E, Riva CE, Hardarson SH, Stefansson E (2008) Regulation of retinal blood flow in health and disease. Prog Retin Eye Res 27:284\u2013330","journal-title":"Prog Retin Eye Res"},{"key":"1153_CR33","first-page":"F104","volume":"252","author":"DM Maurice","year":"1987","unstructured":"Maurice DM (1987) Flow of water between aqueous and vitreous compartments in the rabbit eye. Am J Physiol 252:F104\u2013F108","journal-title":"Am J Physiol"},{"key":"1153_CR34","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/00006982-200410001-00002","volume":"24","author":"LP Aiello","year":"2004","unstructured":"Aiello LP, Brucker AJ, Chang S, Cunningham ET Jr, D'Amico DJ, Flynn HW Jr, Grillone LR, Hutcherson S, Liebmann JM, O'Brien TP, Scott IU, Spaide RF, Ta C, Trese MT (2004) Evolving guidelines for intravitreous injections. Retina 24:S3\u2013S19","journal-title":"Retina"},{"key":"1153_CR35","doi-asserted-by":"crossref","first-page":"5708","DOI":"10.1167\/iovs.07-0731","volume":"48","author":"H Ameri","year":"2007","unstructured":"Ameri H, Chader GJ, Kim JG, Sadda SR, Rao NA, Humayun MS (2007) The effects of intravitreous bevacizumab on retinal neovascular membrane and normal capillaries in rabbits. Invest Ophthalmol Vis Sci 48:5708\u20135715","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1153_CR36","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nprot.2007.4","volume":"2","author":"RN Agrawal","year":"2007","unstructured":"Agrawal RN, He S, Spee C, Cui JZ, Ryan SJ, Hinton DR (2007) In vivo models of proliferative vitreoretinopathy. Nat Protoc 2:67\u201377","journal-title":"Nat Protoc"},{"key":"1153_CR37","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.ajo.2007.03.007","volume":"143","author":"S Peters","year":"2007","unstructured":"Peters S, Heiduschka P, Julien S, Ziemssen F, Fietz H, Bartz-Schmidt KU, Schraermeyer U (2007) Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab. Am J Ophthalmol 143:995\u20131002","journal-title":"Am J Ophthalmol"},{"key":"1153_CR38","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.ophtha.2007.01.017","volume":"114","author":"SJ Bakri","year":"2007","unstructured":"Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ (2007) Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 114:855\u2013859","journal-title":"Ophthalmology"},{"key":"1153_CR39","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1097\/IAE.0b013e318177f934","volume":"28","author":"HA Mintz-Hittner","year":"2008","unstructured":"Mintz-Hittner HA, Kuffel RR Jr (2008) Intravitreal injection of bevacizumab (Avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II. Retina 28:831\u2013838","journal-title":"Retina"},{"key":"1153_CR40","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1016\/j.ophtha.2008.04.023","volume":"115","author":"Q Zhu","year":"2008","unstructured":"Zhu Q, Ziemssen F, Henke-Fahle S, Tatar O, Szurman P, Aisenbrey S, Schneiderhan-Marra N, Xu X, Grisanti S (2008) Vitreous levels of bevacizumab and vascular endothelial growth factor-A in patients with choroidal neovascularization. Ophthalmology 115:1750\u20131755","journal-title":"Ophthalmology"},{"key":"1153_CR41","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/IAE.0b013e3180dc9360","volume":"28","author":"SJ Bakri","year":"2008","unstructured":"Bakri SJ, Pulido JS, Mukherjee P, Marler RJ, Mukhopadhyay D (2008) Absence of histologic retinal toxicity of intravitreal nanogold in a rabbit model. Retina 28:147\u2013149","journal-title":"Retina"},{"key":"1153_CR42","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1097\/01.iae.0000230717.85319.f5","volume":"26","author":"L Feiner","year":"2006","unstructured":"Feiner L, Barr EE, Shui YB, Holekamp NM, Brantley MA Jr (2006) Safety of intravitreal injection of bevacizumab in rabbit eyes. Retina 26:882\u2013888","journal-title":"Retina"},{"key":"1153_CR43","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/00006982-200603000-00001","volume":"26","author":"RP Manzano","year":"2006","unstructured":"Manzano RP, Peyman GA, Khan P, Kivilcim M (2006) Testing intravitreal toxicity of bevacizumab (Avastin). Retina 26:257\u2013261","journal-title":"Retina"},{"key":"1153_CR44","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1097\/00006982-200603000-00002","volume":"26","author":"J Shahar","year":"2006","unstructured":"Shahar J, Avery RL, Heilweil G, Barak A, Zemel E, Lewis GP, Johnson PT, Fisher SK, Perlman I, Loewenstein A (2006) Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina 26:262\u2013269","journal-title":"Retina"},{"key":"1153_CR45","doi-asserted-by":"crossref","first-page":"3438","DOI":"10.1167\/iovs.08-2871","volume":"50","author":"B Avci","year":"2009","unstructured":"Avci B, Avci R, Inan UU, Kaderli B (2009) Comparative evaluation of apoptotic activity in photoreceptor cells after intravitreal injection of bevacizumab and pegaptanib sodium in rabbits. Invest Ophthalmol Vis Sci 50:3438\u20133446. [pii] iovs.08-2871 doi: 10.1167\/iovs.08-2871","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1153_CR46","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1167\/iovs.06-0828","volume":"48","author":"UU Inan","year":"2007","unstructured":"Inan UU, Avci B, Kusbeci T, Kaderli B, Avci R, Temel SG (2007) Preclinical safety evaluation of intravitreal injection of full-length humanized vascular endothelial growth factor antibody in rabbit eyes. Invest Ophthalmol Vis Sci 48:1773\u20131781","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1153_CR47","first-page":"1561","volume":"41","author":"N Alikacem","year":"2000","unstructured":"Alikacem N, Yoshizawa T, Nelson KD, Wilson CA (2000) Quantitative MR imaging study of intravitreal sustained release of VEGF in rabbits. Invest Ophthalmol Vis Sci 41:1561\u20131569","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1153_CR48","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1006\/exer.1996.0239","volume":"64","author":"H Ozaki","year":"1997","unstructured":"Ozaki H, Hayashi H, Vinores SA, Moromizato Y, Campochiaro PA, Oshima K (1997) Intravitreal sustained release of VEGF causes retinal neovascularization in rabbits and breakdown of the blood-retinal barrier in rabbits and primates. Exp Eye Res 64:505\u2013517","journal-title":"Exp Eye Res"},{"key":"1153_CR49","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1076\/ceyr.22.2.140.5528","volume":"22","author":"CG Wong","year":"2001","unstructured":"Wong CG, Rich KA, Liaw LH, Hsu HT, Berns MW (2001) Intravitreal VEGF and bFGF produce florid retinal neovascularization and hemorrhage in the rabbit. Curr Eye Res 22:140\u2013147","journal-title":"Curr Eye Res"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-009-1153-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00417-009-1153-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-009-1153-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T15:40:48Z","timestamp":1559058048000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00417-009-1153-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7,31]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,4]]}},"alternative-id":["1153"],"URL":"https:\/\/doi.org\/10.1007\/s00417-009-1153-z","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,7,31]]}}}